Teva Pharma rises as schizophrenia drug meets main goal of late-stage study

Medincell SA

08/05/2024 12:49

** U.S.-listed shares of Teva Pharmaceuticals  TEVA.N 
 TEVA.TA  rise 3.2% to $14.40 premarket  
    ** The Israel-based co and partner Medincell  MEDCL.PA  say
their injectable form of a schizophrenia drug meets main goal in
a late-stage study
    ** The experimental drug, TEV-'749, helped reduce symptoms
of schizophrenia as measured on a disease severity scale 
    ** TEVA also reports Q1 revenue of $3.82 bln vs $3.66 bln a
year ago 
    ** Posts Q1 adj profit of 48 cents per share, up from 40
cents a year ago  
    ** Up to last close, TEVA up 33.6% YTD  

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))